NextCell Pharma AB (STO:NXTCL)
Sweden · Delayed Price · Currency is SEK 1.170
-0.010 (-0.85%)
Apr 24, 2026, 5:04 PM CET
NextCell Pharma AB Earnings Call Transcripts
Fiscal Year 2025
-
ProTrans, an off-the-shelf cell therapy, demonstrates long-term efficacy and safety in type 1 diabetes, with ongoing pediatric trials and expansion into new indications. Strategic partnerships and subsidiary growth are driving new revenue streams and global reach. Clinical results show preserved insulin production and health benefits.
-
ProTrans-Young, a pediatric trial for type 1 diabetes, shows strong safety and early efficacy trends, with reduced insulin loss and no severe adverse events after one year. The therapy is easy to administer, scalable, and may offer long-term benefits, with full data expected in 2026.